Chasing rivals, AbbVie files migraine prevention drug atogepant in EU
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up […]
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up […]
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in […]
The startup’s asthma solution, called Mya, combines home-based diagnostics, digital health and a care team to identify patients at risk and proactively intervene to prevent […]
This brief provides an overview of the tele-PrEP landscape, including how PrEP services (e.g., consults, lab work, prescribing, and monitoring) are provided and factors that […]
In 2020, only 25% of people who could benefit from pre-exposure prophylaxis (PrEP), a medication that reduces the risk of acquiring HIV, were prescribed it. […]
With the information contained in a simple 30-second voice sample, providers can help patients get ahead of future health issues and prescribe or adjust treatment […]
The company is using the funding to grow its product development and research teams, and expand the clinical services offered by its nurse support team. […]
AbbVie’s Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting […]
Bristol-Myers Squibb’s rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem […]
AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy […]
AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy […]
The delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but there is some good news – the […]
Joe Newhouse has a nice overview article on the value of preventive care in the latest edition of the Journal of Economic Literature. He makes […]
Shots: The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to […]
Shots: The P-III D8110C00001 study involves assessing AZD1222 vs PBO in 32,449 participants in a ratio (2:1) aged ≥18yrs. across 88 trial centers in the […]
Shots: The P-III BLAZE-1 study involves assessing Bamlanivimab (700 mg) + Etesevimab (1400 mg) vs PBO in 769 COVID-19 patients aged ≥12yrs. who are at […]
Melanoma: What You Need to Know About Diagnosis and Treatment Melanoma is an aggressive skin cancer but it is treatable, and even curable, if caught […]
The Affordable Care Act (ACA) requires new private health insurance plans to cover many recommended preventive services without any patient cost-sharing. This tracker presents up-to-date […]
Shots: The approval is based on P-III BLOCKSTONE study assessing a single dose of Xofluza vs PBO in household members who were living with someone […]
Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine […]
People 65 and older, who have been hardest hit by COVID-19 in terms of hospitalizations and deaths, are also at high risk of severe flu […]
The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and […]
The post Can wastewater monitoring help inform future drug prevention strategies? appeared first on Healthy Debate.
Copyright © 2024 | WordPress Theme by MH Themes